Spondyloarthropathy: disease at the crossroads of immunity

Best Practice and Research: Clinical Rheumatology

Volumn 20, Issue 5, 2006, Pages 949-967

  FitzGerald, Oliver ^a   McInnes, Iain ^b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

adaptive immunity; cytokine; innate immunity; synovitis; T lymphocyte

Indexed keywords

ADALIMUMAB; ALEFACEPT; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOSPORIN; DENILEUKIN DIFTITOX; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 23; METHOTREXATE; PROTEIN P40; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; COHORT ANALYSIS; DRUG TARGETING; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOTHERAPY; INNATE IMMUNITY; LYMPHOCYTE FUNCTION; NONHUMAN; PATHOGENESIS; PLASMA CELL; PRIORITY JOURNAL; PSORIASIS; REVIEW; SPONDYLOARTHROPATHY; T LYMPHOCYTE;

ANIMALS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; HUMANS; IMMUNITY, INNATE; IMMUNITY, NATURAL; INTERLEUKIN-1; MONOKINES; PLASMA CELLS; PSORIASIS; SPONDYLARTHROPATHIES; SYNOVIAL FLUID; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33748500241     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2006.06.010     Document Type: Review

References (80)

1. Baeten D., Kruithof E., De Rycke L., et al. Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Research and Therapy 7 2 (2005) R359-R369
2. Ferrell W.R., Lockhart J.C., Kelso E.B., et al. Essential role for proteinase-activated receptor-2 in arthritis. Journal of Clinical Investigation 111 1 (2003) 35-41
3. Akira S., and Takeda K. Toll-like receptor signalling. Nature Reviews. Immunology 4 7 (2004) 499-511
4. Marshak-Rothstein A., Busconi L., Rifkin I.R., and Viglianti G.A. The stimulation of Toll-like receptors by nuclear antigens: a link between apoptosis and autoimmunity. Rheumatic Diseases Clinics of North America 30 3 (2004) 559-574 ix
5. Corr M. The tolls of arthritis. Arthritis and Rheumatism 52 8 (2005) 2233-2236
6. Radstake T.R., van Lieshout A.W., van Riel P.L., et al. Dendritic cells, Fc{gamma} receptors, and toll-like receptors: potential allies in the battle against rheumatoid arthritis. Annals of the Rheumatic Diseases 64 11 (2005) 1532-1538
7. Roelofs M.F., Joosten L.A., Abdollahi-Roodsaz S., et al. The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis and Rheumatism 52 8 (2005) 2313-2322
8. Radstake T.R., Roelofs M.F., Jenniskens Y.M., et al. Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma. Arthritis and Rheumatism 50 12 (2004) 3856-3865
9. Seibl R., Birchler T., Loeliger S., et al. Expression and regulation of toll-like receptor 2 in rheumatoid arthritis synovium. American Journal of Pathology 162 4 (2003) 1221-1227
10. De Rycke L., Vandooren B., Kruithof E., et al. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of toll-like receptor 2 and toll-like receptor 4 in spondyloarthropathy. Arthritis and Rheumatism 52 7 (2005) 2146-2158
11. Raffeiner B., Dejaco C., Duftner C., et al. Between adaptive and innate immunity: TLR4-mediated perforin production by CD28null T-helper cells in ankylosing spondylitis. Arthritis Research and Therapy 7 6 (2005) R1412-R1420
12. van der Paardt M., Crusius J.B., de Koning M.H., et al. No evidence for involvement of the toll-like receptor 4 (TLR4) A896G and CD14-C260T polymorphisms in susceptibility to ankylosing spondylitis. Annals of the Rheumatic Diseases 64 2 (2005) 235-238
13. Seta N., Granfors K., Sahly H., et al. Expression of host defense scavenger receptors in spondyloarthropathy. Arthritis and Rheumatism 44 4 (2001) 931-939
14. Yoshitomi H., Sakaguchi N., Kobayashi K., et al. A role for fungal {beta}-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice. Journal of Experimental Medicine 201 6 (2005) 949-960
15. Kop E.N., Kwakkenbos M.J., Teske G.J., et al. Identification of the epidermal growth factor-TM7 receptor EMR2 and its ligand dermatan sulfate in rheumatoid synovial tissue. Arthritis and Rheumatism 52 2 (2005) 442-450
16. Lande R., Giacomini E., Serafini B., et al. Characterization and recruitment of plasmacytoid dendritic cells in synovial fluid and tissue of patients with chronic inflammatory arthritis. Journal of Immunology 173 4 (2004) 2815-2824
17. Cavanagh L.L., Boyce A., Smith L., et al. Rheumatoid arthritis synovium contains plasmacytoid dendritic cells. Arthritis Research and Therapy 7 2 (2005) R230-R240
18. Jongbloed S.L., Lebre M.C., Fraser A.R., et al. Enumeration and pheotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Arthritis Research and Therapy 8 1 (2005) R15 [E-pub ahead of print]
19. Danning C.L., Illei G.G., Hitchon C., et al. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis and Rheumatism 43 6 (2000) 1244-1256
20. Partsch G., Wagner E., Leeb B.F., et al. T cell derived cytokines in psoriatic arthritis synovial fluids. Annals of the Rheumatic Diseases 57 11 (1998) 691-693
21. Kane D., Gogarty M., O'Leary J., et al. Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. Arthritis and Rheumatism 50 10 (2004) 3286-3295
22. Sfikakis P.P., and Kollias G. Tumor necrosis factor biology in experimental and clinical arthritis. Current Opinion in Rheumatology 15 4 (2003) 380-386
23. Van den Berg W.B. Lessons from animal models of arthritis. Current Rheumatology Reports 4 3 (2002) 232-239
24. Ritchlin C., Haas-Smith S.A., Hicks D., et al. Patterns of cytokine production in psoriatic synovium. Journal of Rheumatology 25 8 (1998) 1544-1552
25. Partsch G., Steiner G., Leeb B.F., et al. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. Journal of Rheumatology 24 3 (1997) 518-523
26. Mease P.J., and Antoni C.E. Psoriatic arthritis treatment: biological response modifiers. Annals of the Rheumatic Diseases 64 supplement 2 (2005) ii78-ii82
27. Goedkoop A.Y., Kraan M.C., Teunissen M.B., et al. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Annals of the Rheumatic Diseases 63 7 (2004) 769-773
28. McInnes I.B., and Gracie J.A. Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheumatoid arthritis. Current Rheumatology Reports 6 5 (2004) 336-342
29. Tan A.L., Marzo-Ortega H., O'Connor P., et al. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Annals of the Rheumatic Diseases 63 9 (2004) 1041-1045
30. Haibel H., Rudwaleit M., Listing J., and Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Annals of the Rheumatic Diseases 64 2 (2005) 296-298
31. Rooney T., Murphy E., Benito M., et al. Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis. Annals of the Rheumatic Diseases 63 11 (2004) 1393-1398
32. Villadsen L.S., Schuurman J., Beurskens F., et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. Journal of Clinical Investigation 112 10 (2003) 1571-1580
33. Mannon P.J., Fuss I.J., Mayer L., et al. Anti-interleukin-12 antibody for active Crohn's disease. New England Journal of Medicine 351 20 (2004) 2069-2079
34. Kokkola R., Sundberg E., Ulfgren A.K., et al. High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis and Rheumatism 46 10 (2002) 2598-2603
35. Foell D., Kane D., Bresnihan B., et al. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford) 42 11 (2003) 1383-1389
36. McInnes I.B., Illei G.G., Danning C.L., et al. IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. Journal of Immunology 167 7 (2001) 4075-4082
37. Reece R.C., Canete J.D., Parsons W.J., et al. Distinct vascular patterns in the synovitis of psoriatic, reactive and rheumatoid arthritis. Arthritis and Rheumatism 42 (1999) 1481-1485
38. Korendowych E., Owen P., Ravindran J., et al. The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis. Rheumatology (Oxford) 44 8 (2005) 1056-1060
39. Riente L., Chimenti D., Pratesi F., et al. Antibodies to tissue transglutaminase and Saccharomyces cerevisiae in ankylosing spondylitis and psoriatic arthritis. Journal of Rheumatology 31 5 (2004) 920-924
40. Cunnane G., Bresnihan B., and FitzGerald O. Immunohistologic analysis of peripheral joint disease in ankylosing spondylitis. Arthritis and Rheumatism 41 1 (1998) 180-182
41. Laloux L., Voisin M.C., Allain J., et al. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Annals of the Rheumatic Diseases 60 4 (2001) 316-321
42. Veale D.J., Barnes L., Rogers S., and FitzGerald O. Immunohistochemical markers for arthritis in psoriasis. Annals of the Rheumatic Diseases 53 7 (1994) 450-454
43. Mahmoud F., Abul H., al Saleh Q., et al. Elevated B-lymphocyte levels in lesional tissue of non-arthritic psoriasis. Journal of Dermatology 26 7 (1999) 428-433
44. Veale D., Yanni G., Rogers S., et al. Reduced synovial membrane ELAM-1 expression, macrophage numbers and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis and Rheumatism 36 (1993) 893-900
45. Costello P., Bresnihan B., O'Farrelly C., and FitzGerald O. Predominance of CD8+ T lymphocytes in psoriatic arthritis. Journal of Rheumatology 26 5 (1999) 1117-1124
46. Costello P.J., Winchester R.J., Curran S.A., et al. Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions that appear antigen driven. Journal of Immunology 166 4 (2001) 2878-2886
47. Curran S.A., FitzGerald O.M., Costello P.J., et al. Nucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by recognizing autoantigens. Journal of Immunology 172 3 (2004) 1935-1944
48. Sieper J., Kingsley G., Palacios-Boix A., et al. Synovial T lymphocyte-specific immune response to Chlamydia trachomatis in Reiter's disease. Arthritis and Rheumatism 34 5 (1991) 588-598
49. Sieper J., Braun J., Wu P., and Kingsley G. T cells are responsible for the enhanced synovial cellular immune response to triggering antigen in reactive arthritis. Clinical and Experimental Immunology 91 1 (1993) 96-102
50. Ackermann B., Staege M.S., Reske-Kunz A.B., et al. Enterobacteria-infected T cells as antigen-presenting cells for cytotoxic CD8 T cells: a contribution to the self-limitation of cellular immune reactions in reactive arthritis?. Journal of Infectious Diseases 175 5 (1997) 1121-1127
51. Kuon W., Lauster R., Bottcher U., et al. Recognition of chlamydial antigen by HLA-B27-restricted cytotoxic T cells in HLA-B*2705 transgenic CBA (H-2k) mice. Arthritis and Rheumatism 40 5 (1997) 945-954
52. Mertz A.K., Wu P., Sturniolo T., et al. Multispecific CD4+ T cell response to a single 12-mer epitope of the immunodominant heat-shock protein 60 of Yersinia enterocolitica in Yersinia-triggered reactive arthritis: overlap with the B27-restricted CD8 epitope, functional properties, and epitope presentation by multiple DR alleles. Journal of Immunology 164 3 (2000) 1529-1537
53. Thiel A., Wu P., Lauster R., et al. Analysis of the antigen-specific T cell response in reactive arthritis by flow cytometry. Arthritis and Rheumatism 43 12 (2000) 2834-2842
54. Kuon W., Holzhutter H.G., Appel H., et al. Identification of HLA-B27-restricted peptides from the Chlamydia trachomatis proteome with possible relevance to HLA-B27-associated diseases. Journal of Immunology 167 8 (2001) 4738-4746
55. Appel H., Kuon W., Kuhne M., et al. Use of HLA-B27 tetramers to identify low-frequency antigen-specific T cells in Chlamydia-triggered reactive arthritis. Arthritis Research and Therapy 6 6 (2004) R521-R534
56. May E., Dulphy N., Frauendorf E., et al. Conserved TCR beta chain usage in reactive arthritis; evidence for selection by a putative HLA-B27-associated autoantigen. Tissue Antigens 60 4 (2002) 299-308
57. May E., Marker-Hermann E., Wittig B.M., et al. Identical T-cell expansions in the colon mucosa and the synovium of a patient with enterogenic spondyloarthropathy. Gastroenterology 119 6 (2000) 1745-1755
58. Boyle L.H., Goodall J.C., Opat S.S., and Gaston J.S. The recognition of HLA-B27 by human CD4(+) T lymphocytes. Journal of Immunology 167 5 (2001) 2619-2624
59. Goodall J.C., Beacock-Sharp H., Deane K.H., and Gaston J.S. Recognition of the 60 kilodalton cysteine-rich outer membrane protein OMP2 by CD4(+) T cells from humans infected with Chlamydia trachomatis. Clinical and Experimental Immunology 126 3 (2001) 488-493
60. Matyszak M.K., Young J.L., and Gaston J.S. Uptake and processing of Chlamydia trachomatis by human dendritic cells. European Journal of Immunology 32 3 (2002) 742-751
61. Boyle L.H., Goodall J.C., and Gaston J.S. Major histocompatibility complex class I-restricted alloreactive CD4+ T cells. Immunology 112 1 (2004) 54-63
62. Marker-Hermann E., Meyer zum Buschenfelde K.H., and Wildner G. HLA-B27-derived peptides as autoantigens for T lymphocytes in ankylosing spondylitis. Arthritis and Rheumatism 40 11 (1997) 2047-2054
63. Frauendorf E., von Goessel H., May E., and Marker-Hermann E. HLA-B27-restricted T cells from patients with ankylosing spondylitis recognize peptides from B*2705 that are similar to bacteria-derived peptides. Clinical and Experimental Immunology 134 2 (2003) 351-359
64. Duchmann R., Lambert C., May E., et al. CD4+ and CD8+ clonal T cell expansions indicate a role of antigens in ankylosing spondylitis; a study in HLA-B27+ monozygotic twins. Clinical and Experimental Immunology 123 2 (2001) 315-322
65. Kuon W., Kuhne M., Busch D.H., et al. Identification of novel human aggrecan T cell epitopes in HLA-B27 transgenic mice associated with spondyloarthropathy. Journal of Immunology 173 8 (2004) 4859-4866
66. Atagunduz P., Appel H., Kuon W., et al. HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis. Arthritis and Rheumatism 52 3 (2005) 892-901
67. Schon M.P., and Boehncke W.H. Psoriasis. New England Journal of Medicine 352 18 (2005) 1899-1912
68. Piskin G., Koomen C.W., Picavet D., et al. Ultraviolet-B irradiation decreases IFN-gamma and increases IL-4 expression in psoriatic lesional skin in situ and in cultured dermal T cells derived from these lesions. Experimental Dermatology 12 2 (2003) 172-180
69. Chang J.C., Smith L.R., Froning K.J., et al. CD8+ T cells in psoriatic lesions preferentially use T-cell receptor V beta 3 and/or V beta 13.1 genes. Proceedings of the National Academy of Sciences of the United States of America 91 20 (1994) 9282-9286
70. Tassiulas I., Duncan S.R., Centola M., et al. Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Human Immunology 60 6 (1999) 479-491
71. Bos J.D., de Rie M.A., Teunissen M.B., and Piskin G. Psoriasis: dysregulation of innate immunity. British Journal of Dermatology 152 6 (2005) 1098-1107
72. Gottlieb S.L., Gilleaudeau P., Johnson R., et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Medicine 1 (1995) 442-447
73. Krueger G.G. Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis. Journal of the European Academy of Dermatology and Venereology 17 supplement 2 (2003) 17-24
74. Feldman S.R., Menter A., and Koo J.Y. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. British Journal of Dermatology 150 2 (2004) 317-326
75. Gordon K.B., Vaishnaw A.K., O'Gorman J., et al. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Archives of Dermatology 139 12 (2003) 1563-1570
76. Kraan M.C., van Kuijk A.W., Dinant H.J., et al. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis and Rheumatism 46 10 (2002) 2776-2784
77. Gordon K.B., Papp K.A., Hamilton T.K., et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. Journal of the American Medical Association 290 23 (2003) 3073-3080
78. Zenz R., Eferl R., Kenner L., et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 437 7057 (2005) 369-375
79. Mease P.J., Gladman D.D., Ritchlin C.T., et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis and Rheumatism 52 10 (2005) 3279-3289
80. Fraser A.D., van Kuijk A.W.R., Westhovens R., et al. A randomized, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Annals of the Rheumatic Diseases 64 6 (2005) 859-864